Synthetic biology is largely under-the-radar on Wall Street, but Intrexon may be on the verge of doing the kinds of deals that will put it front and center in a growth technology.
Greenberg de-spins the spin on HP.
That $4.3 billion offer for the software company doesn't fully take into account its Spotfire business.
Keep these points from its most recent quarter in mind.
With a debt deal that is way too complicated for its own good, clouds might be gathering on the horizon.
It's a crapshoot to play the patent game. Case in point: VirnetX
The maker of materials for fracking is trying to put a positive spin on customers' shift to sand.
Investors closely watching the situation at the enterprise software company shouldn't have been surprised by its disappointing results.
Stock splits might seem enticing, but they're nothing more than illusion promising more than they deliver.
The company has stopped seeking a buyer, so it’s now a red flag on the Watch List.